A Review of Planned, Ongoing Clinical Studies and Recent Development of BNCT in Mainland of China.

Boron neutron capture therapy (BNCT) is a promising cancer treatment modality that combines targeted boron agents and neutron irradiation to selectively destroy tumor cells. In mainland China, the clinical implementation of BNCT has made certain progress, primarily driven by the development of compact neutron source devices. The availability, ease of operation, and cost-effectiveness offered by these compact neutron sources make BNCT more accessible to cancer treatment centers.

Biodistribution studies of boronophenylalanine in different types of skin melanoma.

A study of the B-enriched Boronophenylalanine-fructose complex(BPA-F) infusion procedure in potential BNCT patients, including three skin melanomas of extremities, was performed. B concentration in tumor(T), blood(B), skin(S) were measured to determine tumor/blood(T/B) and skin/blood(S/B) ratios. T/B ratio for three melanoma patients was in the range 1.

Boron neutron capture therapy for malignant melanoma: first clinical case report in China.

A phase I/II clinical trial for treating malignant melanoma by boron neutron capture therapy (BNCT) was designed to evaluate whether the world's first in-hospital neutron irradiator (IHNI) was qualified for BNCT. In this clinical trial planning to enroll 30 patients, the first case was treated on August 19, 2014. We present the protocol of this clinical trial, the treating procedure, and the clinical outcome of this first case.

PGNAA system preliminary design and measurement of In-Hospital Neutron Irradiator for boron concentration measurement.

A prompt gamma neutron activation analysis (PGNAA) system has been recently developed at the 30-kW research reactor In-Hospital Neutron Irradiator (IHNI) in Beijing. Neutrons from the specially designed thermal neutron beam were used. The thermal flux of this beam is 3.